Zimmer Biomet (NYSE:ZBH) capped off the American Orthopedic Surgery Society’s annual meeting this week by inking a deal to distribute CelgenTek Innovations Corp.’s bone trauma technology and the launch of new Persona and OsseoTi knee components.
The Warsaw, Ind.-based orthopedics juggernaut said the deal with CelgenTek includes that company’s N-Force fixation system and iN3 cement for fracture fixation and filling bone voids. The N-Force can be used with Zimmer Biomet’s N-Force Blue bone substitute matrix in the U.S. and the iN3 cement in Europe, the company said.
“The driving focus of Zimmer Biomet’s trauma portfolio has always been to equip surgeons with exceptional tools that can unlock personalized outcomes for patients, whether they are suffering from routine or complex fracture injuries, which is exactly why we have chosen to pursue this partnership with CelgenTek Innovations,” vice president Randy Sessler said in prepared remarks. “The combination of the N-Force fixation system with our N-Force Blue BSM represents ingenuity and stability in an innovative design, and we are excited to include these clinical solutions as part of our focused strategy to serve trauma surgeons and healthcare systems around the globe.”
“We are honored to partner with Zimmer Biomet in expanding the reach and influence of our orthobiologic portfolio with the commercial capabilities of an innovation leader in global musculoskeletal healthcare,” added CelgenTek Innovations CEO Dr. Thomas Russell. “CelgenTek Innovations is positioned at the forefront of clinical innovation in the U.S., Europe and Australia, and in partnership with Zimmer Biomet we aim to accelerate our strategies for ongoing growth.”
CelgenTek Innovations consists of Memphis-based InnoVision and CelgenTek of Shannon, Ireland.
Zimmer Biomet also said its Persona medial congruent bearing and OsseoTi tibial sleeves dropped this week for the Vanguard 360 revision knee system.
“As the market leader and a pioneer in knee replacement, Zimmer Biomet is absolutely focused on supporting surgeons with a steady cadence of innovative clinical portfolio enhancements that set new standards at every stage of care, including total primary and revision procedures,” vice president Todd Davis said in a prepared statement. “In keeping with our long heritage of musculoskeletal innovation, these additions to Persona the personalized knee system, and the Vanguard 360 knee revision system are designed to empower surgeons to deliver personalized outcomes for their patients, while offering compelling clinical and economic value to healthcare systems around the globe.”